Fig. 4
From: A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells
Phenotypic drug screen workflow with Drug Sensitivity Scores (DSS) for 528 oncology drugs. A The drugs were tested in five doses ranging from 1–10,000 nM for 72 h after which viability was measured by Cell Titer-Glo. B Scatter plots showing the Drug Sensitivity Scores (DSS) of individual compounds. The scatter plot on the right highlights outlier compounds (in red) with high DSS values for p60AmotL2-expressing cells, while displaying lower DSS values for control cells. On the left scatter plot, we compare DSS values for WT MDCK cells with and without Dox, accounting for Dox-related effects